모델 기반학적 신약개발에서 약동/약력학 모델링 및 시뮬레이션의 역할

키워드

참고문헌 (41)

1. U.S. Department of Health and Human Services, "Food and Drug Administration (FDA). Challenge and opportunity on the critical path of new medical product", pp.3~11 (2004), FDA reports
2. Biomarker Definition Working Group (BDWG, "National Institutes of Health (NIH). Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework", Clin Pharmacol Ther, 69(3), pp.89~95 (2001)
3. Wagner JA, "Overview of biomarkers and surrogate endpoints in drug development", Dis Markers, 18, pp.41~46 (2002)
4. Colburn WA, "Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development", J Clin Pharmacol, 40, pp.1419~1427 (2000)
5. Food and Drug Administration (FDA).Critical path opportunities reports, "U.S. Department of Health and Human Services", FDA reports, ~ (2006)
6. Food and Drug Administration (FDA). Critical path opportunities lists, "U.S. Department of Health and Human Services", FDA reports, ~ (2006)
7. Food and Drug Administration (FDA). Critical path opportunities generic drugs, "U.S. Department of Health and Human Services", FDA reports, ~ (2007)
8. [URL]
9. [URL]
10. Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: Exposureresponse relationships-study design, data analysis, and regulatory applications, "U.S. Department of Health and Human Services", FDA guidance, ~ (2003)
11. Rene Bruno, "Impact of PK", PD modeling and simulation in drug development, 20th JSSX meetingW, pp.2005[DOI]
12. Shargel L, "Relationship between pharmacokinetics and pharmacodynamics, Applied biopharmaceutics and pharmacokinetics, 4th ed", pp.573~695 (1999), McGraw hill
13. Kwon KI, "Introduction to PK & PD", Proceedings of Biomarker PK, 2007, ~
14. Suri A, "Geisslinger G et al. Pharmacokineticpharmacodynamic relationship for analgesics", Int J Pharm Th, 35(10), pp.414~417 (1997)
15. Deredorf H, "Modeling of pharmacokinetic", pharmacodynamic relationships: Concepts and perspectives, 1999, pp.16(2), 176~185
16. Mager DE, "Minireview: Diversity of mechanism-based pharmacodynamic models", Drug Metab Dispos, 31(5), pp.510~518 (2003)
17. Wagner JG, "Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man", J Theor Biol, 20(2), pp.173~201 (1968)
18. Jose PU, "Pharmacokineticpharmacodynamic modeling: Why?", Med Res, 31, pp.229~239 (2000)
19. Bellissant E, "Methodological issues in pharmacokinetic-pharmacodynamic modelling", Clin Pharmacokinet, 35(2), pp.151~166 (1998)
20. Mager DE, "Quantitiative structure-pharmacokinetic", pharmacodynamic relationships, 2006, pp.58, 1326~1356
21. Shimada S, "Comparative pharmacodynamics of eight calcium channel clocking agents in Japanese esstial hypertensive patients", Biological and Pharmaceutical Bulletin, 19, pp.430~437 (1996)
22. Yun HY, "Pharmacokinetics and pharmacodynamics of benidipine using a slow receptorbinding model", J Clin Pharm Ther, 30, pp.541~547 (2005)
23. Csajka C, "Pharmacokinetic-pharmacodynamic modeling: History and perspectives", J Pharmacokinet Phar, 33(3), pp.227~279 (2006)
24. Smith DE, "Application of effectcompartment model to bumetanide-indomethacin interaction in dogs", J Pharmacokinet Phar, 11(4), pp.355~368 (2005)
25. Danhof M, "Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis", Ann Rev Pharmacol, 47, pp.357~400 (2007)
26. Danhof M, "Modeling biophase distribution. In: Proceeding of course on pharmacokinetic", pharmacodynamic modeling, 2003, ~
27. Dayneka NL, "Comparison of four basic models of indirect pharmacodynamic responses", J Pharmacokinet Phar, 21(4), pp.457~478 (1993)
28. Xu ZX, "Pharmacodynamic modeling of prednisolone effects on natural killer cell tracffiking", Pharm Res, 11, pp.848~854 (1994)
29. Sharma A, "Characteristics of indirect pharmacodynamic models and applications to clinical drug responses", Brit J Clin Pharmaco, 22(7), pp.1038~1049 (1993)
30. Sharma A, "Precursor-dependent indirect pharmacodynamic reponse model for tolerance and rebound phenomena", J Pharm Sci-US, 87(12), pp.1577~1584 (1998)
31. Jusko WJ, "Pharmacodynamics of chemotherapeutic effects: Dose-Time-Reponse relationships for phase-nonspecific agents", J Pharm Sci-US, 60(6), pp.892~895 (1971)
32. Yao Z, "Assessment of basic indirect pharmacodynamic response models with physiological limits", J Pharmacokinet Phar, 33(2), pp.167~193 (2006)
33. Nagashima R, "Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin", Clin Pharmacol Ther, 10, pp.22~35 (1969)
34. Callaghan JT, "Intravenous nizatidine kinetics and acid suppression", Clin Pharmacol Ther, 37, pp.162~165 (1985)
35. Rohatagi S, "Dynamic modeling of crotisol reduction after inhaled administration of fluticasone propionate", J Clin Pharmacol, 36, pp.938~941 (1996)
36. Fisher LE, "Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes", J Pharmcokinet Biopharm, 20, pp.319~331 (1992)
37. Jusko WJ, "Physiologic indirect response models characterize diverse types of pharmacodynamic effects", Clin Pharmacol Ther, 56, pp.406~419 (1994)
38. Bonate PL, "The art of modeling, Pharmacokineticpharmacodynamic modeling and simulation", pp.1~56 (2005), Springer
39. pharmacodynamic systems analysis software. 4th ed., "ADAPT II user’s guide: Pharmacokinetic", pp.1997, D’Argenio DZ
40. [URL]
41. [URL]

관련 논문AI추천